AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37261531
Drug: Eliapixant 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eliapixant 75 mg
Trial: 37261531
Drug: Eliapixant 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eliapixant 150 mg
Trial: 37261654
Drug: Treatment-emergent pain
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent pain interference
Trial: 37261654
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor receipt
Trial: 37261654
Drug: Treatment-emergent endocrine
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent endocrine symptoms
Trial: 37261654
Drug: Treatment-emergent physical
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent physical function decline
Trial: 37261664
Drug: Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valerate 2-6 mg plus spironolactone 100-200 mg
Trial: 37261664
Drug: PrEP (tenofovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP (tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg)
Trial: 37261804
Drug: Camrelizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab (200 mg IV every 2 weeks), Apatinib (250 mg oral once daily), Temozolomide (200 mg/m2 IV once daily on days 1-5)
Trial: 37261831
Drug: Chemotherapy (fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (fluorouracil or capecitabine, with some receiving doublet chemotherapy or bevacizumab)
Trial: 37261831
Drug: Treatment-first group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-first group
Trial: 37261839
Drug: Low-dose atropine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose atropine 0.02%
Trial: 37261839
Drug: Low-dose atropine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose atropine 0.01%
Trial: 37262929
Drug: Saliva insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saliva insulin
Trial: 37262961
Drug: Maintenance rucaparib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance rucaparib (600 mg twice daily)
Trial: 37263673
Drug: KN046 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN046 administered at doses of 1, 3, and 5 mg/kg every 2 weeks (Q2W), 5 mg/kg every 3 weeks (Q3W), and 300 mg Q3W.
Trial: 37263683
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral antibiotics
Trial: 37263914
Drug: Mixed nuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed nuts (42.5 g/day)
Trial: 37264143
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (pre- and postprocedural intravenous hydration)
Trial: 37264295
Drug: Orsiro Mission
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orsiro Mission stent with 1-month dual antiplatelet therapy (DAPT)
Trial: 37264295
Drug: Resolute Onyx
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Resolute Onyx stent with 1-month dual antiplatelet therapy (DAPT)
Trial: 37264321
Drug: Radiotherapy ± chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy ± chemotherapy
Trial: 37264321
Drug: Trans-Oral Robotic
RxNorm normalized name: Rezyst Probiotic Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-Oral Robotic Surgery (TORS)
Trial: 37264993
Drug: Adalimumab (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (subcutaneous administration at doses following the package insert)
Trial: 37265222
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aerobic training and semaglutide treatment
Trial: 37265259
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lenacapavir plus teropavimab and zinlirvimab
Trial: 37265425
Drug: INBRX-109 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INBRX-109 (3 mg/kg every 3 weeks)
Trial: 37265820
Drug: Long-term β-blocker
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term β-blocker therapy
Trial: 37265820
Drug: No β-blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No β-blocker treatment
Trial: 37266942
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg) with standard chemoradiation (cisplatin 100 mg/m2, RT 69.96 Gy) followed by adjuvant bevacizumab (15 mg/kg) with cisplatin (80 mg/m2) and fluorouracil (1000 mg/m2/d)
Trial: 37266940
Drug: Targeted quality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted quality improvement intervention for IV rtPA administration in secondary hospitals
Trial: 37266943
Drug: Bisensory treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisensory treatment (combined auditory and somatosensory) for 30 minutes per day for 6 weeks
Trial: 37266943
Drug: Auditory-only treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auditory-only treatment for 30 minutes per day for 6 weeks
Trial: 37267169
Drug: Managing substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Managing substance use and treatment of OUD
Trial: 37267394
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Melatonin orally daily for two consecutive menstrual cycles
Trial: 37267394
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally daily for two consecutive menstrual cycles
Trial: 37267720
Drug: Serum metabolome,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum metabolome, adiponectin, inflammatory markers, and insulin-like growth factor-binding protein-1 phosphoisoforms analyzed at GDM diagnosis
Trial: 37267720
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IDL cholesterol, early gestational weight gain, fasting and 2-h glucose from oral glucose tolerance test
Trial: 37267804
Drug: GM-CSF 125
RxNorm normalized name: axatilimab-csfr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF 125 μg/m
Trial: 37268010
Drug: More intensive
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More intensive cryotherapy treatment
Trial: 37268157
Drug: Atezolizumab subcutaneous
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab subcutaneous (SC) 1875 mg
Trial: 37268157
Drug: Atezolizumab intravenous
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab intravenous (IV) 1200 mg
Trial: 37268435
Drug: Elamipretide 40
RxNorm normalized name: Elamipretide
DrugBank: Elamipretide (DB11981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elamipretide 40 mg/d for 24 weeks
Trial: 37268656
Drug: Triheptanoin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triheptanoin at maximum tolerable dose
Trial: 37268772
Drug: Medication dose
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication dose
Trial: 37268802
Drug: Face mask
RxNorm normalized name: CVS Face Masks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face mask oxygen therapy
Trial: 37269076
Drug: GSK3739937 (GSK'937)
RxNorm normalized name: GSK-239512
DrugBank: GSK-239512 (DB15120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3739937 (GSK'937) - single doses of 10-800 mg
Trial: 37269076
Drug: GSK3739937 (GSK'937)
RxNorm normalized name: GSK-239512
DrugBank: GSK-239512 (DB15120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3739937 (GSK'937) - multiple doses of 25-100 mg once daily or 500 mg once weekly
Trial: 37269076
Drug: GSK3739937 (GSK'937)
RxNorm normalized name: GSK-239512
DrugBank: GSK-239512 (DB15120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3739937 (GSK'937) - bioavailability as a tablet versus powder-in-bottle
Trial: 37269344
Drug: Brigimadlin (BI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigimadlin (BI 907828) at a maximum tolerated dose of 60 mg for D1q3w and 45 mg for D1D8q4w
Trial: 37269841
Drug: Lutetium-177 PSMA-targeted
RxNorm normalized name: Lutetium dotatate Lu-177
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutetium-177 PSMA-targeted radioligand therapy
Trial: 37269870
Drug: Nangibotide 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nangibotide 0.3 mg/kg per h (low-dose group)
Trial: 37269870
Drug: Nangibotide 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nangibotide 1.0 mg/kg per h (high-dose group)
Trial: 37269870
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (placebo, low-dose, high-dose)
Trial: 37269909
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose blueberry powder (2.5%)
Trial: 37269909
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose blueberry powder (5%)
Trial: 37269941
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 0.5 mg/kg once daily for 14 days
Trial: 37269941
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 1 mg/kg once daily for 7 days
Trial: 37269941
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 1 mg/kg twice daily for 3.5 days
Trial: 37270027
Drug: Breastfeeding with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breastfeeding with at least 1 daily meal of Cows' Milk Formula (CMF)
Trial: 37270188
Drug: Eye-movement desensitisation
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eye-movement desensitisation and reprocessing therapy (EMDR) plus standard neuropsychiatric care (NPC)
Trial: 37270201
Drug: Routine data
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine data (Aspirin)
Trial: 37270289
Drug: Teduglutide 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide 0.05 mg/kg/d for 48 weeks
Trial: 37270471
Drug: Myofascial release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial release therapy (MRT)
Trial: 37270517
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg twice daily for 8 weeks
Trial: 37270698
Drug: Tepotinib, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepotinib, 500 mg once daily
Trial: 37271356
Drug: Preventive PCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive PCI plus optimal medical therapy (OMT)
Trial: 37271412
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 3600 mg per day
Trial: 37271416
Drug: 60-mg ferrous
RxNorm normalized name: ferrous fumarate 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-mg ferrous sulfate
Trial: 37271416
Drug: 18-mg ferrous
RxNorm normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18-mg ferrous bisglycinate
Trial: 37271706
Drug: Fourth dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fourth dose of NVX-CoV2373 (5 µg rS protein + 50 µg Matrix-M adjuvant)
Trial: 37271706
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of NVX-CoV2373
Trial: 37271706
Drug: Fourth dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fourth dose of NVX-CoV2373
Trial: 37271818
Drug: Ivermectin mass
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin mass drug administration to humans and/or livestock
Trial: 37272513
Drug: Neoadjuvant pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant pembrolizumab (200 mg) plus cisplatin-based chemotherapy for 4 cycles, followed by surgery and adjuvant pembrolizumab (200 mg) for up to 13 cycles.
Trial: 37272513
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus cisplatin-based chemotherapy for 4 cycles, followed by surgery and placebo for up to 13 cycles.
Trial: 37272521
Drug: Dupilumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (300 mg) subcutaneously once every 2 weeks
Trial: 37273224
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (NTG) 0.2-0.6 mg/h
Trial: 37273420
Drug: Ceralasertib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceralasertib monotherapy 160 mg BID continuously
Trial: 37273420
Drug: Acalabrutinib 100
RxNorm normalized name: acalabrutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 100 mg BID followed by ceralasertib 160 mg BID 1 week on/3 weeks off
Trial: 37273449
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oral risedronate for six months
Trial: 37273942
Drug: Ulotaront (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulotaront (25, 50, or 75 mg/d)
Trial: 37275963
Drug: Ribociclib (600-mg/day)
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib (600-mg/day)
Trial: 37276067
Drug: Tislelizumab 200
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200 mg every 3 weeks (Cohort 3)
Trial: 37276067
Drug: Tislelizumab 200
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200 mg every 3 weeks (Cohort 1)
Trial: 37276067
Drug: Tislelizumab 200
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200 mg every 3 weeks (Cohort 2)
Trial: 37276451
Drug: Pegaspargase 2000
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegaspargase 2000 IU/m2 added to courses 1, 2, 5, and 6 of an 8-block chemotherapy protocol.
Trial: 37276451
Drug: Pegaspargase treatment
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegaspargase treatment with allogeneic hematopoietic cell transplantation (HCT)
Trial: 37276451
Drug: Pegaspargase treatment
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegaspargase treatment
Trial: 37276496
Drug: MS2003-SR (modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS2003-SR (modified Berlin-Frankfurt-Muenster ALL-IC2002 protocol with 120 mg/m² anthracycline)
Trial: 37276510
Drug: Treatment Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Choice (TC) - azacitidine, decitabine, or low-dose cytarabine
Trial: 37276510
Drug: Treatment Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Choice (TC)
Trial: 37276510
Drug: Treatment Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Choice (TC) (in patients receiving ≥4 cycles)
Trial: 37276871
Drug: Zanidatamab 20
RxNorm normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanidatamab 20 mg/kg intravenously every 2 weeks
Trial: 37276913
Drug: Half-dose quadruple
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose quadruple therapy (irbesartan 75 mg + metoprolol 23.75 mg + amlodipine 2.5 mg + indapamide 1.25 mg)
Trial: 37276913
Drug: Standard-dose dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose dual therapy (irbesartan 150 mg + amlodipine 5 mg)
Trial: 37276947
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant follicle-stimulating hormone (rFSH) treatment
Trial: 37277100
Drug: Standard reminiscence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard reminiscence therapy
Trial: 37277217
Drug: Intensive lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid lowering (LDL-C of <1.8 mmol/L or ≥50% reduction from the baseline)
Trial: 37277217
Drug: Moderate-intensity lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity lipid lowering (LDL-C of <2.6 mmol/L or 30%-49% reduction from the baseline)
Trial: 37277219
Drug: Rhythm control
RxNorm normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhythm control therapies
Trial: 37277454
Drug: Camonsertib (RP-3500)
RxNorm normalized name: Camonsertib
DrugBank: Camonsertib (DB18888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camonsertib (RP-3500) at a recommended phase 2 dose of 160 mg weekly on days 1-3
Trial: 37277703
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block (ESPB) with 20 ml of bupivacaine 0.25% (n=50)
Trial: 37277703
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with 20 ml saline injection (n=50)
Trial: 37278638
Drug: Intraplantar injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraplantar injection of cancer exosomes
Trial: 37278760
Drug: Integrating sublingual
RxNorm normalized name: mecobalamin 1000 MCG Disintegrating Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrating sublingual microcirculatory perfusion variables in the therapy plan
Trial: 37278858
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus low-dose temozolomide (50 mg/m²)
Trial: 37278858
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus low-dose temozolomide (50 mg/m²)
Trial: 37278879
Drug: Adavosertib (AZD1775)
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib (AZD1775) 175 mg orally twice a day on days 1-3 and 8-10 of a 21-day treatment cycle
Trial: 37278968
Drug: D-galactose supplementation
RxNorm normalized name: D(+)-Galactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-galactose supplementation (1.5 g/kg/day for 6 months)
Trial: 37278972
Drug: GB223 (7,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB223 (7, 21, 63, 119, or 140 mg)
Trial: 37278999
Drug: Peer health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer health coaching intervention for 12 months with educational materials, automatic blood pressure monitor, scale, pill organizer, and healthy nutrition tools.
Trial: 37279000
Drug: Ticagrelor-aspirin (180-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor-aspirin (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-90)
Trial: 37279000
Drug: Clopidogrel-aspirin (300-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel-aspirin (300-mg loading dose on day 1 followed by 75 mg/d for days 2-90)
Trial: 37279000
Drug: Ticagrelor-aspirin among
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor-aspirin among poor metabolizers
Trial: 37279000
Drug: Clopidogrel-aspirin among
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel-aspirin among poor metabolizers
Trial: 37279034
Drug: New insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New insulin pump
Trial: 37279301
Drug: Riluzole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole (100 mg BID for 24 hours, then 50 mg BID for 13 days)
Trial: 37279602
Drug: Oral camostat
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral camostat for 7 days
Trial: 37279641
Drug: MMM CBT
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMM CBT treatment (9-13 sessions)
Trial: 37279709
Drug: Caffeine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (2.5 mg/kg, twice over 24 h)
Trial: 37279797
Drug: ONC201 (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 (625 mg weekly)
Trial: 37279836
Drug: Degradable Hydrogel
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degradable Hydrogel for sustained localized delivery of anti-tumor drugs; specific dosage and duration not mentioned.
Trial: 37279836
Drug: Direct intratumoral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct intratumoral injection of a drug; specific dosage and duration not mentioned.